- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals Inc stock price live, this page displays NASDAQ ENTA stock exchange data. View the ENTA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Enanta Pharmaceuticals Inc real time stock price chart below.
What Is the Enanta Pharmaceuticals Inc Stock Price Today?
The Enanta Pharmaceuticals Inc stock price today is 8.10.
What Is the Stock Symbol for Enanta Pharmaceuticals Inc?
The stock symbol for Enanta Pharmaceuticals Inc is ""ENTA.""
What Stock Exchange Does Enanta Pharmaceuticals Inc Trade On?
Enanta Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Enanta Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Enanta Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ENTA quote. (ISIN: US29251M1062)
What Is the Enanta Pharmaceuticals Inc Stock Price Today?
The Enanta Pharmaceuticals Inc stock price today is 8.10.
What Is the Stock Symbol for Enanta Pharmaceuticals Inc?
The stock symbol for Enanta Pharmaceuticals Inc is ""ENTA.""
What Stock Exchange Does Enanta Pharmaceuticals Inc Trade On?
Enanta Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Enanta Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Enanta Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ENTA quote. (ISIN: US29251M1062)
8.10
+0.07(+0.87%)
Closed·
After Hours
8.100.00(0.00%)
·
Fair Value
An estimate of a Enanta's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.86
8.15
52 wk Range
4.09
15.17
ENTA Scorecard
Full Analysis
High shareholder yield
Earnings results expected in 12 days
More Info
Fair Value
An estimate of a Enanta's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.868.15
52 wk Range
4.0915.17
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ENTA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Enanta's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
17.75
Upside
+119.14%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Enanta Pharmaceuticals Inc Company Profile
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals Inc SWOT Analysis
Pipeline Progress | Enanta's diverse drug pipeline, including RSV and immunology programs, positions the company for potential breakthroughs in viral infections and liver diseases |
Financial Fortitude | Strong cash position with $193M and extended runway into FY2028 provides stability, despite recent stock decline and cash burn concerns |
Market Dynamics | Analyst price targets range from $5 to $38, reflecting varied perspectives on Enanta's potential in the competitive pharmaceutical landscape |
Strategic Expansion | Explore Enanta's move into immunology, including oral KIT and STAT6 inhibitors, broadening its therapeutic reach beyond antiviral treatments |
Enanta Pharmaceuticals Inc Earnings Call Summary for Q2/2024
- Q2 revenue at $17.1M, mainly from MAVYRET royalties; $300M cash on hand to fund operations through Q3 2027
- Advancing RSV treatments: zelicapavir and EDP-323 in Phase 2; data expected H2 2024 and Q3 2024 respectively
- KIT inhibitor for CSU in development; candidate selection expected Q4 2024
- Updated guidance: R&D expenses $125-145M, G&A $50-60M; exploring additional indications for KIT inhibitor
- Ongoing patent litigation against Pfizer regarding RSV treatment
Last Updated: 07/05/2024, 18:08
Read Full TranscriptCompare ENTA to Peers and Sector
Metrics to compare | ENTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipENTAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −1.7x | −0.5x | |
PEG Ratio | −0.07 | −0.01 | 0.00 | |
Price/Book | 1.9x | 2.4x | 2.6x | |
Price / LTM Sales | 2.7x | 40.0x | 3.2x | |
Upside (Analyst Target) | 146.6% | 231.5% | 42.0% | |
Fair Value Upside | Unlock | 29.9% | 6.6% | Unlock |
Analyst Ratings
3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 17.75
(+119.14% Upside)
Earnings
Latest Release
May 12, 2025
EPS / Forecast
-1.06 / -1.16
Revenue / Forecast
14.90M / 15.95M
People Also Watch
FAQ
What Stock Exchange Does Enanta Trade On?
Enanta is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Enanta?
The stock symbol for Enanta is "ENTA."
What Is the Enanta Market Cap?
As of today, Enanta market cap is 173.15M.
What Is Enanta's Earnings Per Share (TTM)?
The Enanta EPS (TTM) is -4.54.
When Is the Next Enanta Earnings Date?
Enanta will release its next earnings report on 10 Aug 2025.
From a Technical Analysis Perspective, Is ENTA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Enanta Stock Split?
Enanta has split 0 times.
How Many Employees Does Enanta Have?
Enanta has 131 employees.
What is the current trading status of Enanta (ENTA)?
As of 30 Jul 2025, Enanta (ENTA) is trading at a price of 8.10, with a previous close of 8.03. The stock has fluctuated within a day range of 7.86 to 8.15, while its 52-week range spans from 4.09 to 15.17.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.